Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Ovarian Neoplasms 4Neoplasm Metastasis 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Mesothelioma 1Fallopian Tube Neoplasms 1Extensive Stage Lung Small Cell Carcinoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Ovarian Cancer 1

Interventions

gallium Ga 68 dotatate 3Specimen Handling 3Temozolomide 2Radiotherapy 2Magnetic Resonance Spectroscopy 26-fluorodopamine 2tipifarnib 1talazoparib 1pazopanib 1olaparib 1lutetium Lu 177 dotatate 1guadecitabine 1fostamatinib 1fluorodopa F 18 1Tamoxifen 1Surgical Procedures, Operative 1Ritonavir 1Oxaliplatin 1Nivolumab 1Leucovorin 1Ipilimumab 1Indinavir 1Fluorodeoxyglucose F18 1Floxuridine 1Doxorubicin 1Contrast Media 1Cisplatin 1CTLA-4 Antigen 1Biopsy 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Pheochromocytoma × talazoparib × Clear all
NCT05142241 2025-11-18

Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
14 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡